DUBLIN, Calif., Oct. 31, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. ASTX, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced the acceptance of three abstracts for presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Poster presentations will occur Nov 7 – 9 in Dublin, Ireland.
XIAP | Abstract #85, Poster Board #052 | ||
Poster Presentation: | Wednesday, Nov 7, 2012 | 12:00 – 2:15 pm GMT | |
Characterization of a potent XIAP and cIAP1 dual antagonist in models of melanoma and leukemia | |||
AT13387 | Abstract #293, Poster Board #043 | ||
Poster Presentation: | Thursday, Nov 8, 2012 | 12:00 – 2:15 pm GMT | |
Activity of the HSP90 inhibitor, AT13387, in ALK-driven tumor models | |||
SGI-110 | Abstract #465, Poster Board #036 | ||
Poster Presentation | Friday, Nov 9, 2012 | 8:30 – 10:30 am GMT | |
SGI-110, a novel second generation DNA hypomethylating agent, enhances sorafenib activity and alters methylation signature of HCC cell lines |
Select posters will be made available for viewing on the company's website http://astx.com/pipeline/publications/ following the public presentation.
About Astex Pharmaceuticals
Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed DACOGEN® (decitabine) for Injection and receives significant royalties on global sales.
For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.
The Astex Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=12273
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.